Skip to main content
SpringerLink
Log in
Book cover

Nitric Oxide and Cancer: Pathogenesis and Therapy pp 97–109Cite as

S-Nitrosylation in Cancer Cells: To Prevent or to Cause?

  • Chapter
  • First Online:

  • 740 Accesses

Abstract

The purpose of this review is to point out some important proteins targeted by chemotherapy in cancer patients as well as by NO (S-nitrosylation) in tumor cells. We, therefore, confronted data from clinical and preclinical studies and discussed their respective anti-tumor effects to determine whether the associations of chemotherapy with NO donor therapy may be considered as novel therapeutic approaches (considered as rational therapeutic interventions).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

AR:

Androgen receptor

CCL4:

(C-C motif) ligand 4

DETANO:

Diethylenetriamine/nitric oxide

EGF:

Epidermal growth factor

EGFR:

Epidermal growth factor receptor

ERK:

Extracellular signal-regulated kinase

Fas (APO-1, CD95):

Apoptosis antigen 1

GSNO:

S-nitrosoglutatione

GTN:

Glyceryltrinitrate

HER:

Human epidermal growth factor receptor

HSP:

Heat shock protein

IAP:

Inhibitor of apoptosis protein

IKK:

IκB kinase

JNK:

c-jun NH2-terminal kinase

N2O3 :

Nitrogen trioxide

NF-κB:

Nuclear factor-kappa B

NO:

Nitric oxide

NO2 :

Nitrites

NO-NSAIDs:

NO-donating non-steroidal anti-inflammatory drugs

PKB:

Protein kinase B

PTEN:

Phosphatase and TENsin homolog

SM:

Smac mimetic

SNO:

S-nitrosothiol

STAT3:

Signal transduction and activator of transcription 3

TKI:

Tyrosine kinase inhibitor

TRAIL:

Tumor-necrosis-factor related apoptosis inducing ligand

References

  1. Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. J Biol Chem. 2013;288:26473–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Martinez-Ruiz A, Araujo IM, Izquierdo-Alvarez A, Hernansanz-Agustin P, Lamas S, Serrador JM. Specificity in S-nitrosylation: a short-range mechanism for NO signaling? Antioxid Redox Signal. 2013;19:1220–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Aranda E, Lopez-Pedrera C, De La Haba-Rodriguez JR, Rodriguez-Ariza A. Nitric oxide and cancer: the emerging role of S-nitrosylation. Current Molecular Medicine. 2012;12:50–67.

    Article  CAS  PubMed  Google Scholar 

  4. Lander HM, Ogiste JS, Pearce SF, Levi R, Novogrodsky A. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J Biol Chem. 1995;270:7017–20.

    Article  CAS  PubMed  Google Scholar 

  5. Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2010;2:a000158.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Napetschnig J, Wu H. Molecular basis of NF-kB signaling. Annu Rev Biophys. 2013;42: 443–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EF, van der Vliet A, Janssen-Heininger YM. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci USA. 2004;101:8945–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE. NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem. 2007;282:30667–72.

    Article  CAS  PubMed  Google Scholar 

  9. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry. 2001;40:1688–93.

    Article  CAS  PubMed  Google Scholar 

  10. Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336:25–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-kB signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010;298:204–11.

    Article  CAS  PubMed  Google Scholar 

  12. May MJ, D’Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000;289:1550–4.

    Article  CAS  PubMed  Google Scholar 

  13. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res. 2006;12:950–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Wu L, Shao L, Li M, Zheng J, Wang J, Feng W, Chang J, Wang Y, Hauer-Jensen M, Zhou D. BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. Radiat Res. 2013;179:160–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S, Naoe T. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 2013;3:e166.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013;335:145–52.

    Article  CAS  PubMed  Google Scholar 

  17. Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, Park SY, Zhou T, He G, Kim Y, et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 2013;23:213–27.

    CAS  PubMed  Google Scholar 

  18. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2:694–705.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Kim J, Won JS, Singh AK, Sharma AK, Singh I. STAT3 regulation by S-Nitrosylation: implication for inflammatory disease. Antioxid Redox Signal. 2014;20:2514–27.

    Google Scholar 

  20. Dobi E, Monnien F, Kim S, Ivanaj A, N’Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013;12:28–36.

    Article  CAS  PubMed  Google Scholar 

  21. Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014;3:399–411.

    Google Scholar 

  22. Qin Y, Dey A, Purayil HT, Daaka Y. Maintenance of androgen receptor inactivation by S-nitrosylation. Cancer Res. 2013;73:6690–9.

    Article  CAS  PubMed  Google Scholar 

  23. Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology. 2009;74:878–83.

    Article  PubMed  Google Scholar 

  24. Izumi K, Chang C. Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression. Oncoimmunology. 2013;2:e26853.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Leon-Bollotte L, Subramaniam S, Cauvard O, Plenchette-Colas S, Paul C, Godard C, Martinez-Ruiz A, Legembre P, Jeannin JF, Bettaieb A. S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology. 2011;140: 2009–18,18e1–4.

    Article  CAS  PubMed  Google Scholar 

  26. Tang Z, Bauer JA, Morrison B, Lindner DJ. Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol Cell Biol. 2006;26:5588–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–63.

    Article  CAS  PubMed  Google Scholar 

  28. Martinez-Lostao L, Marzo I, Anel A, Naval J. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol. 2012;83:1475–83.

    Article  CAS  PubMed  Google Scholar 

  29. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553–63.

    Article  CAS  PubMed  Google Scholar 

  30. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34:8690–707.

    Article  CAS  PubMed  Google Scholar 

  31. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13:663–73.

    Article  CAS  PubMed  Google Scholar 

  32. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.

    Article  CAS  PubMed  Google Scholar 

  33. Estrada C, Gómez C, Martín-Nieto J, De Frutos T, Jiménez A, Villalobo A. Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochem J. 1997;326:369–76.

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Murillo-Carretero M, Torroglosa A, Castro C, Villalobo A, Estrada C. S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity. Free Radic Biol Med. 2009;46:471–9.

    Article  CAS  PubMed  Google Scholar 

  35. Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 2012;10:1203–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs. 2008;9:614–30.

    CAS  PubMed  Google Scholar 

  37. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.

    Article  CAS  PubMed  Google Scholar 

  38. Feng X, Sun T, Bei Y, Ding S, Zheng W, Lu Y, Shen P. S-nitrosylation of ERK inhibits ERK phosphorylation and induces apoptosis. Sci Rep. 2013;3:1814.

    PubMed Central  PubMed  Google Scholar 

  39. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209–19.

    Article  CAS  PubMed  Google Scholar 

  40. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439: 358–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26:2139–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. So HS, Park RK, Kim MS, Lee SR, Jung BH, Chung SY, Jun CD, Chung HT. Nitric oxide inhibits c-Jun N-terminal kinase 2 (JNK2) via S-nitrosylation. Biochem Biophys Res Commun. 1998;247:809–13.

    Article  CAS  PubMed  Google Scholar 

  43. Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, Jacks T, Davis RJ. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol. 2011;31:1565–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.

    Article  CAS  PubMed  Google Scholar 

  45. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.

    Article  CAS  PubMed  Google Scholar 

  46. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA, Kaneki M. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem. 2005;280:7511–8.

    Article  CAS  PubMed  Google Scholar 

  49. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252–75.

    Article  CAS  PubMed  Google Scholar 

  50. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 2007;12:1543–68.

    Article  CAS  PubMed  Google Scholar 

  51. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–61.

    Article  CAS  PubMed  Google Scholar 

  52. LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett. 2013;332:215–24.

    Article  CAS  PubMed  Google Scholar 

  53. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol. 2009;27:1660–6.

    Article  CAS  PubMed  Google Scholar 

  54. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, Miller RS, Yi H, Shangary S, Sun Y, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008;68:9384–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013;19:1784–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–81.

    Article  CAS  PubMed  Google Scholar 

  57. Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res. 2009;69:7729–38.

    Article  CAS  PubMed  Google Scholar 

  58. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 2004;305:1471–4.

    Article  CAS  PubMed  Google Scholar 

  59. Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Target Ther. 2013;9:1285–304.

    Article  Google Scholar 

  60. Infante JR DE, Burris HA, Zawel L, Sager JA, Stevenson C, Clarke K, Dhuria S, Porter D, Sen SK, et al. Paper presented at: 101st Annual meeting of the American association for cancer research. 2010, and Washington DP, PA. Abstract nr 2775.; 2010.

    Google Scholar 

  61. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;58:636–9.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Chung KK. S-nitrosylation of XIAP compromises neuronal survival in Parkinson’s disease. Proc Natl Acad Sci USA. 2009;106:4900–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Nakamura T, Wang L, Wong CC, Scott FL, Eckelman BP, Han X, Tzitzilonis C, Meng F, Gu Z, Holland EA. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell. 2010;39:184–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Pillai RN, Ramalingam SS. Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr Opin Oncol. 2014;26:159–64.

    Article  CAS  PubMed  Google Scholar 

  65. De Mattos-Arruda L, Cortes J. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype? Breast. 2012;21:604–7.

    Article  PubMed  Google Scholar 

  66. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Target. 2003;3:301–23.

    Article  CAS  Google Scholar 

  67. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Psaltopoulou T. Hsp90 inhibitors in breast cancer: a systematic review. Breast. 2013;22:569–78.

    Article  PubMed  Google Scholar 

  68. Scroggins BT, Neckers L. Just say NO: nitric oxide regulation of Hsp90. EMBO Rep. 2009;10:1093–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Wandinger SK, Suhre MH, Wegele H, Buchner J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 2006;25:367–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Martínez-Ruiz A, Villanueva L, González de Orduña C, López-Ferrer D, Higueras MA, Tarín C, Rodríguez-Crespo I, Vázquez J, Lamas S. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA. 2005;102:8525–30.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Retzlaff M, Stahl M, Eberl HC, Lagleder S, Beck J, Kessler H, Buchner J. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 2009;10:1147–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta. 2012;1823:648–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2006;24:688–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No conflict statement: “any potential conflicts of interest were disclosed.”

Author information

Authors and Affiliations

  1. Immunology and Immunotherapy of Cancer Laboratory, Burgundy University, EA 7269, EPHE, 7 Bd Jeanne d’Arc, 21079, Dijon, France

    Ali Bettaieb, Stéphanie Plenchette, Catherine Paul, Véronique Laurens, Sabrina Romagny & Jean-Fran|ois Jeannin

  2. EPHE, 75014, Paris, France

    Ali Bettaieb, Stéphanie Plenchette, Catherine Paul, Véronique Laurens, Sabrina Romagny & Jean-Fran|ois Jeannin

Authors
  1. Ali Bettaieb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphanie Plenchette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Véronique Laurens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabrina Romagny
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Fran|ois Jeannin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Bettaieb .

Editor information

Editors and Affiliations

  1. Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California of Los Angeles, Los Angeles, California, USA

    Benjamin Bonavida

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bettaieb, A., Plenchette, S., Paul, C., Laurens, V., Romagny, S., Jeannin, JF. (2015). S-Nitrosylation in Cancer Cells: To Prevent or to Cause?. In: Bonavida, B. (eds) Nitric Oxide and Cancer: Pathogenesis and Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-13611-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation